利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

19 条记录 (耗时 0.053 秒)

    METHODS OF SENSITIZING CANCER TO THERAPY-INDUCED CYTOTOXICITY
    6.
    发明申请
    METHODS OF SENSITIZING CANCER TO THERAPY-INDUCED CYTOTOXICITY 审中-公开
    刺激癌症治疗诱导的细胞毒性的方法

    公开(公告)号：US20090148445A1

    公开(公告)日：2009-06-11

    申请号：US12282343

    申请日：2006-11-06

    申请人： Benjamin Bonavida ,  Michael A. Palladino

    发明人： Benjamin Bonavida ,  Michael A. Palladino

    IPC分类号： A61K39/395 ,  A61K31/407 ,  A61K31/69 ,  A61P35/00

    CPC分类号： A61K31/43

    摘要： The present application demonstrates that Salinosporamide A can be used to sensitize cancer cells to cancer therapy. Furthermore, the present application demonstrates that Salinosporamide A acts as a therapeutic agent to kill or inhibit cancer cells after sensitization of the cells by an antibody or other chemosensitizing reagents. The cancer cells can be either therapy-sensitive or therapy resistant. The present application further demonstrates that Salinosporamide A induces the expression of Raf kinase inhibitor protein (RKIP) and PTEN, tumor suppressor proteins, and inhibits the expression of YY1, a transcriptional regulator protein overexpressed in cancer cells and also inhibits the growth factor pleiotrophin (PTN).

    摘要翻译： 本申请表明，Salinosporamide A可用于使癌细胞对癌症治疗敏感。 此外，本申请表明，Salinosporamide A作为治疗剂，用于通过抗体或其它化学敏化试剂致敏细胞后杀死或抑制癌细胞。 癌细胞可以是治疗敏感的或抗药性的。 本申请进一步表明，Salinosporamide A诱导Raf激酶抑制蛋白（RKIP）和PTEN，肿瘤抑制蛋白的表达，并抑制YY1的表达，YY1是癌细胞中过表达的转录调节蛋白，并且还抑制生长因子多潜养蛋白（PTN ）。

    Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
    7.
    发明授权
    Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof 有权
    脱氢苯基乙二烯和其类似物，以及脱氢苯基黑曲霉素及其类似物的合成

    公开(公告)号：US07935704B2

    公开(公告)日：2011-05-03

    申请号：US11051268

    申请日：2005-02-04

    申请人： Michael A. Palladino ,  George Kenneth Lloyd ,  Yoshio Hayashi ,  Benjamin Nicholson

    发明人： Michael A. Palladino ,  George Kenneth Lloyd ,  Yoshio Hayashi ,  Benjamin Nicholson

    IPC分类号： A61K31/497

    CPC分类号： A61K31/496

    摘要： Compounds represented by the following structure (I) are disclosed: as are methods for making such compounds, wherein said methods comprise reacting a diacyldiketopiperazine with a first aldehyde to produce an intermediate compound; and reacting the intermediate compound with a second aldehyde to produce the class of compounds with the generic structure, where the first aldehyde and the second aldehydes are selected from the group consisting of an oxazolecarboxaldeyhyde, imidazolecarboxaldehyde, a benzaldehyde, imidazolecarboxaldehyde derivatives, and benzaldehyde derivatives, thereby forming the above compound wherein R1, R1′, R1″, R2, R3, R4, R5, and R6, X1 and X2, Y, Z, Z1, Z2, Z3, and Z4 may each be separately defined in a manner consistent with the accompanying description. Compositions and methods for treating vascular proliferation are also disclosed.

    摘要翻译： 公开了由以下结构（I）表示的化合物：制备这种化合物的方法，其中所述方法包括使二酰基二酮哌嗪与第一醛反应以产生中间体化合物; 并使所述中间体化合物与第二醛反应以产生一类具有通式结构的化合物，其中第一种醛和第二种醛选自恶唑烷羧醛，咪唑甲醛，苯甲醛，咪唑甲醛衍生物和苯甲醛衍生物， 从而形成上述化合物，其中R1，R1'，R1“，R2，R3，R4，R5和R6，X1和X2，Y，Z，Z1，Z2，Z3和Z4各自可以以一致的方式分别定义 附带说明。 还公开了治疗血管增生的组合物和方法。

    Method and compositions for the treatment and prevention of septic shock
    9.
    发明授权
    Method and compositions for the treatment and prevention of septic shock 失效
    用于治疗和预防痉挛的方法和组合物

    公开(公告)号：US5055447A

    公开(公告)日：1991-10-08

    申请号：US371484

    申请日：1989-06-27

    申请人： Michael A. Palladino ,  Stephen A. Sherwin

    发明人： Michael A. Palladino ,  Stephen A. Sherwin

    IPC分类号： A61K38/00 ,  A61K38/18 ,  A61K38/27 ,  A61K39/395 ,  A61K39/40 ,  A61K45/06 ,  A61P31/04 ,  A61P37/08

    CPC分类号： A61K45/06 ,  A61K38/1841 ,  A61K39/395

    摘要： Methods and compositions are provided for the treatment or prophylaxis of septic shock caused by bacteremic infection. Therapeutically and prophylactically effective doses of transforming growth factor-beta are administered to patients, either alone or in combination with another therapeutic or prophylactic agent for treating this pathologic condition. Preferably, the transforming growth factor-beta is human transforming growth factor-beta, and most preferably TGF-.beta..sub.1, TGF-.beta..sub.2, or TGF-.beta..sub.3.

    摘要翻译： 提供方法和组合物用于治疗或预防由菌血症感染引起的败血性休克。 将治疗和预防有效剂量的转化生长因子-β单独或与用于治疗该病理状况的另一种治疗或预​​防剂组合施用于患者。 优选地，转化生长因子-β是人转化生长因子-β，最优选TGF-β1，TGF-β2或TGF-β3。